PROJECT

Projects

Summary of Proposed Investment

Project Number

21947

Company Name

Euromedic Diagnostics B.V. & International Hemodialysis Centers B.V.

Date SPI Disclosed

Dec 23, 2003

Country

Southern Europe Subregion

Industry

Health, Education and Life Sciences

Projected Board Date

Jan 26, 2004

Status

Completed

Sector

Hospitals and Clinics

Department

Regional Industry MAS LAC & EUR

Environmental Category

B - Limited

Previous Events

Approved : Mar 4, 2004
Signed : Mar 12, 2004
Invested : Jun 4, 2004

Project Description

The Euromedic group of companies, a leading provider of diagnostic imaging and hemodialysis services in Central, Eastern and Southern Europe and an existing IFC client is undertaking further expansion in the region.

An estimated $23 million project is designed to expand the existing network of Euromedic’s diagnostic and hemodialysis centers in Poland, Hungary, Romania and Bosnia (which was partially financed by the first IFC loan) and to establish similar operations in other countries in the region. Most existing centers are certified to the ISO 9002 quality management system international standard, and new centers are in the process of becoming certified. Each center has (or will have) established policies and procedures related to patient and employee health and safety and waste management.


Through the project, Euromedic is extending high quality private healthcare to large and diverse portions of local population thus improving both access to and equity of services. The diagnostic centers are expected to speed the delivery of high quality imaging that will enable faster and more accurate treatment of patients. Euromedic hemodialysis centers have the potential to save the lives of hundreds of patients who would die within weeks of developing end stage renal disease (ESRD) without access to treatment. In addition, by improving the quality of dialysis care, Euromedic will contribute to cost savings due to reduced annual hospitalization and shorter length of annual disability of ESRD patients.

Sponsor / Cost / Location

Development Impact